From the laboratory to the clinic: How translational studies in animals have lead to clinical advances in boron neutron capture therapy.

In this report five examples have been selected to illustrate how studies in experimental animals have lead directly to clinical implementation. These include (1) the use of BSH as a boron delivery agent for BNCT of patients with brain tumors, and more specifically gliomas; (2) the use of BPA as a delivery agent for BNCT for patients with melanomas and (3) its subsequent use for BNCT of patients with gliomas; (4) optimization of the delivery of BPA in patients with gliomas; and finally (5) the combination of BSH and BPA with BNCT alone or together with X-irradiation to treat patients with gliomas.